BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 25093288)

  • 1. Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary.
    Vierkoetter KR; Ayabe AR; VanDrunen M; Ahn HJ; Shimizu DM; Terada KY
    Gynecol Oncol; 2014 Oct; 135(1):81-4. PubMed ID: 25093288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
    Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
    Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
    Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas.
    Rambau PF; Duggan MA; Ghatage P; Warfa K; Steed H; Perrier R; Kelemen LE; Köbel M
    Histopathology; 2016 Aug; 69(2):288-97. PubMed ID: 26799366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
    Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
    Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
    Chui MH; Ryan P; Radigan J; Ferguson SE; Pollett A; Aronson M; Semotiuk K; Holter S; Sy K; Kwon JS; Soma A; Singh N; Gallinger S; Shaw P; Arseneau J; Foulkes WD; Gilks CB; Clarke BA
    Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.
    Garg K; Leitao MM; Kauff ND; Hansen J; Kosarin K; Shia J; Soslow RA
    Am J Surg Pathol; 2009 Jun; 33(6):925-33. PubMed ID: 19238076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic analysis with immunohistochemistry for DNA mismatch repair protein expression in synchronous primary endometrial and ovarian cancers.
    Kobayashi Y; Nakamura K; Nomura H; Banno K; Irie H; Adachi M; Iida M; Umene K; Nogami Y; Masuda K; Kisu I; Ueki A; Yamagami W; Kataoka F; Hirasawa A; Tominaga E; Susumu N; Aoki D
    Int J Gynecol Cancer; 2015 Mar; 25(3):440-6. PubMed ID: 25695547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High homogeneity of MMR deficiency in ovarian cancer.
    Fraune C; Rosebrock J; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Höflmayer D; Schmalfeldt B; Müller V; Wölber L; Witzel I; Paluchowski P; Wilke C; Heilenkötter U; von Leffern I; Clauditz TS; Wilczak W; Sauter G; Steurer S; Burandt E
    Gynecol Oncol; 2020 Mar; 156(3):669-675. PubMed ID: 31924330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.
    Hodan R; Kingham K; Cotter K; Folkins AK; Kurian AW; Ford JM; Longacre T
    Cancer Med; 2021 Feb; 10(3):1012-1017. PubMed ID: 33369189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
    Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
    Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma.
    Latham A; Shia J; Patel Z; Reidy-Lagunes DL; Segal NH; Yaeger R; Ganesh K; Connell L; Kemeny NE; Kelsen DP; Hechtman JF; Nash GM; Paty PB; Zehir A; Tkachuk KA; Sheikh R; Markowitz AJ; Mandelker D; Offit K; Berger MF; Cercek A; Garcia-Aguilar J; Saltz LB; Weiser MR; Stadler ZK
    Clin Cancer Res; 2021 Mar; 27(5):1429-1437. PubMed ID: 33199489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.
    Mills AM; Liou S; Ford JM; Berek JS; Pai RK; Longacre TA
    Am J Surg Pathol; 2014 Nov; 38(11):1501-9. PubMed ID: 25229768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis.
    Mitric C; Salman L; Abrahamyan L; Kim SR; Pechlivanoglou P; Chan KKW; Gien LT; Ferguson SE
    Gynecol Oncol; 2023 Mar; 170():133-142. PubMed ID: 36682091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome?
    Soliman PT; Broaddus RR; Schmeler KM; Daniels MS; Gonzalez D; Slomovitz BM; Gershenson DM; Lu KH
    J Clin Oncol; 2005 Dec; 23(36):9344-50. PubMed ID: 16361634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors.
    Ketabi Z; Bartuma K; Bernstein I; Malander S; Grönberg H; Björck E; Holck S; Nilbert M
    Gynecol Oncol; 2011 Jun; 121(3):462-5. PubMed ID: 21388660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas.
    Djordjevic B; Barkoh BA; Luthra R; Broaddus RR
    Mod Pathol; 2013 Oct; 26(10):1401-12. PubMed ID: 23599155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
    Carr C; Son J; Yao M; Priyadarshini A; Marquard J; Vargas R; Michener C; AlHilli MM
    Gynecol Oncol; 2020 Dec; 159(3):712-720. PubMed ID: 33046272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.